|
FR104F
(cg-RX-API-DMAC7.html)
|
1960-11-05 |
|
|
|
|
US3117160A
(en)
|
1961-07-27 |
1964-01-07 |
Pfizer & Co C |
Aralkylamines
|
|
US3198834A
(en)
|
1964-07-27 |
1965-08-03 |
Snc Science Union Et Compagnie |
Optical isomers of trifluoromethylated phenethylamines
|
|
GB1254332A
(en)
|
1969-02-27 |
1971-11-17 |
Science Union & Cie |
Amino acids and their derivatives and processes for preparing them
|
|
DE2143204C3
(de)
|
1971-08-28 |
1979-09-27 |
Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt |
N-Fluoralkyl-phenylisopropylamin-Derivate und deren Salze, Verfahren zu deren Herstellung und Arzneimittel auf deren Basis
|
|
DE2150399A1
(de)
|
1971-10-09 |
1973-04-12 |
Hoechst Ag |
Neue oxime
|
|
GB1413070A
(en)
|
1973-07-27 |
1975-11-05 |
Beecham Group Ltd |
Process for the production of - norfenfluramine and - fenfluramine and salts thereof
|
|
GB1413078A
(en)
|
1973-07-27 |
1975-11-05 |
Beecham Group Ltd |
Process for the production of plus-norfenfluramine and plus-fenfluramine and salts thereof
|
|
US4309445A
(en)
|
1980-06-16 |
1982-01-05 |
Massachusetts Institute Of Technology |
d-Fenfluramine for modifying feeding behavior
|
|
US4452815A
(en)
|
1980-06-16 |
1984-06-05 |
Massachusetts Institute Of Technology |
Method of utilizing d,l-fenfluramine for modifying feeding behavior
|
|
DE3717434C1
(de)
|
1987-05-23 |
1988-09-15 |
Degussa |
Verfahren zur Herstellung von m-Trifluormethylphenylacetonitril
|
|
US4857553A
(en)
|
1987-08-06 |
1989-08-15 |
A. H. Robins Company, Incorporated |
Method of treating nausea and vomiting with certain substituted-phenylalkylamino (and aminoacid) derivatives and other serotonin depleting agents
|
|
KR890003368A
(ko)
|
1987-08-06 |
1989-04-14 |
원본미기재 |
특정의 치환된 페닐알킬아미노(및 아미노산) 유도체 및 기타 세로토닌농도 저하제로 오심 및 구토를 치료하는 방법
|
|
HU204497B
(en)
|
1989-10-09 |
1992-01-28 |
Chinoin Gyogyszer Es Vegyeszet |
Process for producing phenfluramine
|
|
IT1238686B
(it)
|
1990-02-09 |
1993-09-01 |
Lab Mag Spa |
Procedimento per la preparazione di levo e destro fenfluramina
|
|
FR2684552B1
(fr)
|
1991-12-06 |
1995-04-28 |
Adir |
Utilisation de la d-fenfluramine et de derives de la fenfluramine dans le traitement de l'hypertension chez des sujets insulino-resistants.
|
|
US5985880A
(en)
|
1996-06-05 |
1999-11-16 |
Delta Pharmaceuticals |
Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
|
|
US5708018A
(en)
|
1993-08-06 |
1998-01-13 |
Pharmacia & Upjohn Company |
2-aminoindans as selective dopamine D3 ligands
|
|
US5834477A
(en)
|
1993-12-08 |
1998-11-10 |
The United States Of America As Represented By The Secretary Of The Army |
Opiate analgesic formulation with improved safety
|
|
US5412102A
(en)
|
1994-05-27 |
1995-05-02 |
Syntex (U.S.A.) Inc. |
Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid
|
|
EP0762877B1
(en)
|
1994-06-03 |
2001-03-21 |
THEJMDE Trust |
Meta substituted arylalkylamines and therapeutic and diagnostic uses thereof
|
|
IT1298349B1
(it)
|
1996-05-29 |
2000-01-05 |
Alfa Chem Ital |
Processo per la produzione di 1 - (3-trifluorometil) fenil-propan- 2-one intermedio nella sintesi della fenfluramina
|
|
IT1292885B1
(it)
|
1997-04-28 |
1999-02-11 |
Alfa Chem Ital |
Processo per la produzione degli isomeri (r) ed (s)- alfa -metil-3- (trifluorometil)benzene-etanamina.
|
|
EP0920864A1
(en)
|
1997-12-03 |
1999-06-09 |
Pfizer Products Inc. |
Combination therapy including a specific beta-3 agonist and an anorectic agent
|
|
US20020098175A1
(en)
|
1998-06-16 |
2002-07-25 |
Zohoungbogbo Mathias C. |
Dietetic food composition and dietetic method using such composition
|
|
US6045501A
(en)
|
1998-08-28 |
2000-04-04 |
Celgene Corporation |
Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
|
|
ATE238783T1
(de)
|
1998-12-23 |
2003-05-15 |
Orphan Medical Inc |
Mikrobenbeständige und stabilisierte lösungen, die gamma-hydroxybuttersäuresalze zur behandlung von narkolepsie enthalten
|
|
US20080103179A1
(en)
|
2006-10-27 |
2008-05-01 |
Tam Peter Y |
Combination Therapy
|
|
US7124031B1
(en)
|
2000-05-11 |
2006-10-17 |
Medco Health Solutions, Inc. |
System for monitoring regulation of pharmaceuticals from data structure of medical and labortory records
|
|
US20020032581A1
(en)
|
2000-07-17 |
2002-03-14 |
Reitberg Donald P. |
Single-patient drug trials used with accumulated database: risk of habituation
|
|
US6315720B1
(en)
|
2000-10-23 |
2001-11-13 |
Celgene Corporation |
Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
|
|
US7585493B2
(en)
|
2001-05-24 |
2009-09-08 |
Alexza Pharmaceuticals, Inc. |
Thin-film drug delivery article and method of use
|
|
US6737042B2
(en)
|
2001-05-24 |
2004-05-18 |
Alexza Molecular Delivery Corporation |
Delivery of drug esters through an inhalation route
|
|
ES2339339T3
(es)
|
2001-06-22 |
2010-05-19 |
Universite Catholique De Louvain |
Perlas o capsulas de hidrogel como medios artificiales para la oviposicion de insectos y la cria de endoparasitoides.
|
|
WO2003011306A1
(en)
|
2001-07-31 |
2003-02-13 |
Wyeth |
Sucralose formulations to mask unpleasant tastes
|
|
AUPR732601A0
(en)
|
2001-08-28 |
2001-09-20 |
Polychip Pharmaceuticals Pty Ltd |
Methods for the synthesis of amines such as ephedrine and inter mediates
|
|
RU2317104C2
(ru)
|
2001-09-24 |
2008-02-20 |
Импиэриэл Инноувейшнс Лимитид |
Способ модификации пищевого поведения и применение pyy или его агониста в качестве средства для модификации пищевого поведения
|
|
ATE419863T1
(de)
|
2001-09-24 |
2009-01-15 |
Imp Innovations Ltd |
Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit
|
|
US6599901B1
(en)
|
2001-11-19 |
2003-07-29 |
Hoffman-La Roche Inc. |
Pyridone substituted benzothiazole derivatives
|
|
US7101572B2
(en)
*
|
2001-12-07 |
2006-09-05 |
Unilab Pharmatech, Ltd. |
Taste masked aqueous liquid pharmaceutical composition
|
|
WO2003077847A2
(en)
|
2002-03-12 |
2003-09-25 |
Merck & Co., Inc. |
Substituted amides
|
|
JP2005531520A
(ja)
|
2002-03-28 |
2005-10-20 |
メルク エンド カムパニー インコーポレーテッド |
置換２，３−ジフェニルピリジン類
|
|
US7668730B2
(en)
|
2002-12-17 |
2010-02-23 |
JPI Commercial, LLC. |
Sensitive drug distribution system and method
|
|
WO2005004865A1
(en)
|
2003-07-08 |
2005-01-20 |
Georg-August-Universität Göttingen |
Use of 5-ht4(a)-serotonin receptor agonists
|
|
GB0410266D0
(en)
|
2004-05-07 |
2004-06-09 |
Ketocytonyx Inc |
Treatment of apoptosis
|
|
US9820658B2
(en)
|
2006-06-30 |
2017-11-21 |
Bao Q. Tran |
Systems and methods for providing interoperability among healthcare devices
|
|
CA2602899A1
(en)
|
2005-03-21 |
2006-09-28 |
Software Solutions Limited |
System for continuous blood pressure monitoring
|
|
US20060270611A1
(en)
|
2005-05-25 |
2006-11-30 |
Dries Willy M A |
Pediatric formulation of topiramate
|
|
NZ564892A
(en)
|
2005-06-16 |
2011-10-28 |
Bionomics Ltd |
Methods of treatment, and diagnosis of epilepsy by detecting a D674G mutation in the SCN1A gene
|
|
GB0515090D0
(en)
|
2005-07-22 |
2005-08-31 |
Birmingham Res & Dev Ltd |
Novel epilepsy treatment
|
|
EP1937255A4
(en)
|
2005-09-14 |
2013-06-26 |
Univ Witwatersrand Jhb |
PHARMACEUTICAL COMPOSITION
|
|
EP3223182A1
(en)
|
2005-11-29 |
2017-09-27 |
Children's Hospital Medical Center |
Optimization and individualization of medication selection and dosing
|
|
US7592461B2
(en)
|
2005-12-21 |
2009-09-22 |
Bristol-Myers Squibb Company |
Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
|
CA2637792A1
(en)
|
2006-02-06 |
2007-08-16 |
Novartis Ag |
Combination of organic compounds
|
|
DE102006030113B4
(de)
|
2006-06-28 |
2009-02-12 |
Chemische Fabrik Budenheim Kg |
Graphitfreier Hochtemperatur-Schmierstoff
|
|
CA2660431C
(en)
|
2006-08-31 |
2015-03-17 |
The Governors Of The University Of Alberta |
Method of inhibition of respiratory depression using positive allosteric ampa receptor modulators
|
|
EP2115648A2
(en)
|
2007-01-31 |
2009-11-11 |
Quintiles Transnational Corp., Inc. |
Methods and systems for site startup
|
|
WO2008104524A1
(en)
|
2007-02-28 |
2008-09-04 |
Smithkline Beecham Corporation |
Thiadiazole derivatives, inhibitors of stearoyl-coa desaturase
|
|
GB2456183A
(en)
|
2008-01-04 |
2009-07-08 |
Gw Pharma Ltd |
Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
|
|
JP5714910B2
(ja)
|
2008-01-09 |
2015-05-07 |
チャールストン ラボラトリーズ，インコーポレイテッド |
薬学的組成物
|
|
JP2011529923A
(ja)
|
2008-08-06 |
2011-12-15 |
ゴスフォース センター（ホールディングス）プロプライエタリー リミテッド |
精神障害（ｐｓｙｃｈｉａｔｒｉｃｄｉｓｏｒｄｅｒ）を治療するための組成物および方法
|
|
WO2010020585A1
(en)
|
2008-08-18 |
2010-02-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Serotonin reuptake inhibitors for the treatment of rett syndrome
|
|
JP5731387B2
(ja)
|
2008-09-05 |
2015-06-10 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
医薬配合剤
|
|
US8386274B1
(en)
|
2008-09-17 |
2013-02-26 |
Mckesson Financial Holdings Limited |
Systems and methods for a prescription safety network utilizing eligibility verification transactions
|
|
CA2737391A1
(en)
*
|
2008-10-09 |
2010-04-15 |
Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. |
Liquid pharmaceutical formulation containing paracetamol
|
|
WO2010042780A2
(en)
|
2008-10-10 |
2010-04-15 |
The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of Walter Reed Army Institute Of Research |
Methods and compositions for treating status epilepticus and seizures causing status epilepticus
|
|
TWI424832B
(zh)
|
2008-12-15 |
2014-02-01 |
Proteus Digital Health Inc |
與身體有關的接收器及其方法
|
|
US20120065999A1
(en)
|
2009-03-09 |
2012-03-15 |
Celgene Corporation |
Device for Delivering a Drug to a Patient While Restricting Access to the Drug by Patients for Whom the Drug May Be Contraindicated and Methods for Use Thereof
|
|
WO2010121022A1
(en)
|
2009-04-15 |
2010-10-21 |
Research Triangle Institute |
Monoamine reuptake inhibitors
|
|
US20100324936A1
(en)
|
2009-04-22 |
2010-12-23 |
Suresh-Kumar Venkata Vishnubhatla |
Pharmacy management and administration with bedside real-time medical event data collection
|
|
US9453027B2
(en)
|
2009-07-27 |
2016-09-27 |
Daljit Singh Dhanoa |
Deuterium-enriched pyridinonecarboxamides and derivatives
|
|
AR079862A1
(es)
|
2010-01-08 |
2012-02-22 |
Eurand Inc |
Composicion de topiramato con sabor enmascarado, un comprimido desintegrable oralmente que comprende la misma y metodo de preparacion
|
|
AU2011224520B2
(en)
|
2010-03-09 |
2016-04-21 |
Perceptimed, Inc. |
Medication verification and dispensing
|
|
WO2011119227A2
(en)
|
2010-03-25 |
2011-09-29 |
Columbia Northwest Pharmaceuticals, Llc |
Compositions for the treatment of central nervous system disorders including depression employing novel drug combination therapy to reduce suicidality in patients
|
|
JP2011221623A
(ja)
|
2010-04-06 |
2011-11-04 |
Kakimori Suri |
在宅診療支援システム及び方法
|
|
ES2687095T3
(es)
|
2010-05-21 |
2018-10-23 |
Research Triangle Institute |
Fenilimorfolinas y análogos de las mismas
|
|
EP2399513B1
(en)
|
2010-06-23 |
2017-01-04 |
Qatar University Qstp-B |
System for non-invasive automated monitoring, detection, analysis, characterisation, prediction or prevention of seizures and movement disorder symptoms
|
|
CN103108651A
(zh)
|
2010-07-30 |
2013-05-15 |
默沙东公司 |
Cyp3a药物代谢的抑制
|
|
CN103189053A
(zh)
|
2010-09-01 |
2013-07-03 |
艾尼纳制药公司 |
用于体重控制的5-ht2c激动剂的调节释放剂型
|
|
US20120270848A1
(en)
|
2010-10-22 |
2012-10-25 |
Galleon Pharmaceuticals, Inc. |
Novel Compositions and Therapeutic Methods Using Same
|
|
AU2011322147A1
(en)
|
2010-10-26 |
2013-04-18 |
Alpharma Pharmaceuticals, Llc |
Formulations and methods for attenuating respiratory depression induced by opioid overdose
|
|
RU103209U1
(ru)
|
2010-10-29 |
2011-03-27 |
Общество С Ограниченной Ответственностью "Правовое Сопровождение Бизнеса" |
Клиническая информационная система
|
|
GB2487712B
(en)
|
2011-01-04 |
2015-10-28 |
Otsuka Pharma Co Ltd |
Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
|
|
JP5693325B2
(ja)
|
2011-03-29 |
2015-04-01 |
小林クリエイト株式会社 |
健診結果出力システム及び健診結果出力プログラム
|
|
GB201111712D0
(en)
|
2011-07-08 |
2011-08-24 |
Gosforth Ct Holdings Pty Ltd |
Pharmaceutical compositions
|
|
WO2013096878A1
(en)
|
2011-12-22 |
2013-06-27 |
University Of Idaho |
Garcinia buchananii baker compounds, compositions and related methods
|
|
US9346798B2
(en)
|
2012-02-13 |
2016-05-24 |
Amgen Inc. |
Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
|
|
US20130218586A1
(en)
|
2012-02-21 |
2013-08-22 |
Frederic J. Huser |
Methods and elements for identifying the appropriate patient populations who can safely use prescription chronic care drugs that are switched to an over-the-counter regulatory status
|
|
JP6075973B2
(ja)
|
2012-06-04 |
2017-02-08 |
富士通株式会社 |
健康状態判定装置およびその作動方法
|
|
US20150291597A1
(en)
|
2012-11-15 |
2015-10-15 |
Galleon Pharmaceuticals, Inc. |
Novel orally bioavailable breathing control modulating compounds, and methods of using same
|
|
WO2014106825A2
(en)
|
2013-01-06 |
2014-07-10 |
Jonathan Rabinowitz |
Methods and devices for identifying improper medical reporting
|
|
US9549909B2
(en)
|
2013-05-03 |
2017-01-24 |
The Katholieke Universiteit Leuven |
Method for the treatment of dravet syndrome
|
|
HUE053282T2
(hu)
|
2013-08-19 |
2021-06-28 |
Univ California |
Vegyületek és eljárások epilepsziás rendellenesség kezelésére
|
|
WO2015066344A1
(en)
|
2013-11-01 |
2015-05-07 |
Arena Pharmaceuticals, Inc. |
5-ht2c receptor agonists and compositions and methods of use
|
|
WO2015077057A1
(en)
|
2013-11-20 |
2015-05-28 |
Texas Southern University |
Methionine aminopeptidase inhibitors for treating infectious diseases
|
|
CN103886415A
(zh)
|
2014-03-25 |
2014-06-25 |
北京蝶禾谊安信息技术有限公司 |
药品管理方法和装置
|
|
GB2530001B
(en)
|
2014-06-17 |
2019-01-16 |
Gw Pharma Ltd |
Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
|
|
AU2015326472B2
(en)
|
2014-09-29 |
2020-05-28 |
Zogenix International Limited |
Control system for control of distribution of medication
|
|
GB2531282A
(en)
|
2014-10-14 |
2016-04-20 |
Gw Pharma Ltd |
Use of cannabinoids in the treatment of epilepsy
|
|
JP2018504420A
(ja)
|
2015-02-06 |
2018-02-15 |
マリナス ファーマシューティカルズ インコーポレイテッド |
静注用ガナキソロン製剤ならびにてんかん重積状態および他の発作性障害の治療におけるその使用
|
|
EP4043016B1
(en)
|
2015-02-25 |
2025-10-29 |
The Regents of the University of California |
The 5ht agonist clemizole for use in treating epilepsy disorders
|
|
US10292996B2
(en)
|
2015-03-26 |
2019-05-21 |
The Trustees Of Columbia University In The City Of New York |
Deoxyribonucleoside monophospate bypass therapy for mitochondrial DNA depletion syndrome
|
|
PL3310362T3
(pl)
|
2015-06-17 |
2020-04-30 |
The Trustees Of Columbia University In The City Of New York |
Terapia deoksynukleozydowa chorób spowodowanych przez niezrównoważoną pulę nukleotydów włączając zespół deplecji mitochondrialnego DNA
|
|
RU2734506C2
(ru)
|
2015-06-30 |
2020-10-19 |
Нейрад Лтд. |
Новые модулирующие регуляцию дыхания соединения и способы их получения и применения
|
|
WO2017015309A1
(en)
|
2015-07-22 |
2017-01-26 |
John Hsu |
Composition comprising a therapeutic agent and a respiratory stimulant and methods for the use thereof
|
|
DK3340971T3
(da)
|
2015-08-24 |
2024-05-27 |
Zogenix International Ltd |
Fremgangsmåder til behandling af lennox-gastaut syndrom ved anvendelse af fenfluramin
|
|
US20170071949A1
(en)
|
2015-09-14 |
2017-03-16 |
Zogenix International Limited |
Combination treatment of specific forms of epilepsy
|
|
EP3170807B1
(en)
|
2015-11-23 |
2019-12-11 |
Frau Pharma S.r.l. |
New method for synthesis of fenfluramine
|
|
FI3800177T3
(fi)
*
|
2015-12-22 |
2025-04-29 |
Zogenix International Ltd |
Fenfluramiinikoostumukset ja menetelmät niiden valmistamiseksi
|
|
US20170174614A1
(en)
|
2015-12-22 |
2017-06-22 |
Zogenix International Limited |
Metabolism resistant fenfluramine analogs and methods of using the same
|
|
WO2017122701A1
(ja)
|
2016-01-14 |
2017-07-20 |
旭硝子株式会社 |
フッ素樹脂含有溶液、フッ素樹脂含有溶液の製造方法、塗料組成物および塗装物品
|
|
EP4201427A1
(en)
|
2016-08-24 |
2023-06-28 |
Zogenix International Limited |
Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
|
|
US20180092864A1
(en)
|
2016-09-30 |
2018-04-05 |
Zogenix International Limited |
Compositions and methods for treating seizure disorders
|
|
WO2018206924A1
(en)
|
2017-05-09 |
2018-11-15 |
Zogenix International Limited |
Methods of treating doose syndrome using fenfluramine
|
|
US10682317B2
(en)
|
2017-09-26 |
2020-06-16 |
Zogenix International Limited |
Ketogenic diet compatible fenfluramine formulation
|
|
WO2019067413A1
(en)
|
2017-09-26 |
2019-04-04 |
Zogenix International Limited |
USE OF A FENFLURAMINE FORMULATION TO REDUCE THE NUMBER AND FREQUENCIES OF CONVULSIVE CRISES IN PATIENT POPULATIONS
|
|
US20190091179A1
(en)
|
2017-09-26 |
2019-03-28 |
Zogenix International Limited |
Congnitive function with fenfluramine
|
|
CN112312929A
(zh)
|
2018-04-18 |
2021-02-02 |
纽约市哥伦比亚大学理事会 |
用于包括线粒体dna耗竭综合征在内的由不平衡的核苷酸库引起的疾病的基因疗法
|
|
US11571397B2
(en)
|
2018-05-11 |
2023-02-07 |
Zogenix International Limited |
Compositions and methods for treating seizure-induced sudden death
|
|
US10517841B1
(en)
|
2018-06-14 |
2019-12-31 |
Zogenix International Limited |
Compositions and methods for treating respiratory depression with fenfluramine
|
|
JP2021530481A
(ja)
|
2018-07-10 |
2021-11-11 |
ゾゲニクス インターナショナル リミテッド |
肺高血圧症を有さない患者においててんかんまたはてんかん性脳症を処置するために使用するためのフェンフルラミン
|
|
CA3117868A1
(en)
|
2018-11-19 |
2020-05-28 |
Zogenix International Limited |
Methods of treating rett syndrome using fenfluramine
|
|
EP3887481A4
(en)
|
2018-11-30 |
2022-08-03 |
Zogenix International Limited |
METHODS OF TREATMENT OF REFRACTORY EPILEPSY SYNDROMES USING FENFLURAMINE ENANTIOMERS
|
|
JP2022521446A
(ja)
|
2019-02-25 |
2022-04-07 |
ゾゲニクス インターナショナル リミテッド |
発作制御を改善するための製剤
|
|
US20210299064A1
(en)
|
2020-02-05 |
2021-09-30 |
Zogenix International Limited |
Method of treating patients with lennox-gastaut syndrome
|
|
US11612574B2
(en)
|
2020-07-17 |
2023-03-28 |
Zogenix International Limited |
Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
|
|
US20220096514A1
(en)
|
2020-09-29 |
2022-03-31 |
Zogenix International Limited |
Methods of treating thymidine kinase 2 deficiency by administering deoxycytidine and deoxythymidine
|